Rhythm Pharmaceuticals Inc. (RYTM) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Rhythm Pharmaceuticals In... (RYTM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

53.94

-0.95 (-1.73%)

At close: Jan 14, 2025, 3:59 PM

53.94

0.01%

Pre-market Jan 15, 2025, 07:32 AM EST

undefined% (undefined)

Bid	52.01
Market Cap	3.31B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.32
PE Ratio (ttm)	-12.48
Forward PE	n/a
Analyst	Buy

Ask	57.98
Volume	435,856
Avg. Volume (20D)	560,404
Open	55.14
Previous Close	54.89
Day's Range	53.14 - 55.75
52-Week Range	35.17 - 68.58
Beta	undefined

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström sy...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 9, 2017

Employees 226

Stock Exchange NASDAQ

Ticker Symbol RYTM

Website https://www.rhythmtx.com

Analyst Forecast

According to 10 analyst ratings, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is $67.5, which is an increase of 25.15% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Rhythm Pharmaceuticals Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of $37.99M, reflecting a 56.76% YoY growth and earnings per share of -0.74, making a 5.71% increase YoY.

Why Price Moved

2 months ago · Source

+11.38%

Rhythm Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

3 months ago · Source

+7.37%

Rhythm Pharmaceuticals shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $64.

News

3 weeks ago · benzinga.com

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. RYTM, a developer of treatment for rare obesity disorders.

2 months ago · seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications D...

2 months ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.76 per share a year ago.

2 months ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.